|
116
|
348
|
5aikA |
Human dyrk1a in complex with ldn-211898 |
|
84
|
297
|
5cwzA |
Crystal structure of the kinase domain of human traf2 and nck-interacting protein kinase |
|
92
|
294
|
4ypdA |
Crystal structure of dapk1 catalytic domain in complex with the hinge binding fragment 4-methylpyridazine |
|
116
|
325
|
5cu3A |
Crystal structure of ck2alpha with compound 10 bound |
|
64
|
276
|
5d10A |
Kinase domain of csrc in complex with rl236 |
|
112
|
327
|
5cu4A |
Crystal structure of ck2alpha with compound 10 bound |
|
84
|
274
|
4yznA |
Humanized roco4 bound to compound 19 |
|
99
|
323
|
5cziA |
Egfr l858r mutant in complex with a shc peptide substrate |
|
101
|
328
|
5cquA |
Monoclinic complex structure of protein kinase ck2 catalytic subunit with a benzotriazole-based inhibitor generated by click-chemistry |
|
101
|
289
|
4ythA |
Discovery of vx-509 (decernotinib): a potent and selective janus kinase (jak) 3 inhibitor for the treatment of autoimmune diseases |
|
107
|
402
|
4yzdA |
Crystal structure of human phosphorylated ire1alpha in complex with adp-mg |
|
94
|
277
|
5cxhA |
Syk catalytic domain complexed with a potent orally bioavailable thiazole inhibitor |
|
60
|
276
|
4yzmA |
Humanized roco4 bound to lrrk2-in1 |
|
111
|
327
|
5cvfA |
Crystal structure of ck2alpha with compound 5 bound |
|
77
|
298
|
5d1jA |
Crystal structure of cyclin-dependent kinase 2 (cdk2-wt) complex with n-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl] methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide (bms-387032) |
|
111
|
326
|
5ct0A |
Crystal structure of ck2alpha with 3-(3-chloro-4-(phenyl)benzylamino)propan-1-ol bound |
|
102
|
297
|
4yo6A |
Irak4-inhibitor co-structure |
|
156
|
475
|
4ysmA |
Calcium-dependent protein kinase from eimeria tenella |
|
78
|
273
|
5ct7A |
Braf in complex with raf265 |
|
92
|
323
|
5czhA |
Egfr l858r mutant in complex with an optimal peptide substrate |
|
119
|
348
|
4yllA |
Crystal structure of dyrk1aa in complex with 10-bromo-substituted 11h-indolo[3,2-c]quinolone-6-carboxylic acid inhibitor 5t |
|
123
|
461
|
4ygaA |
Cdpk1, from toxoplasma gondii, bound to inhibitory vhh-1b7 |
|
86
|
294
|
4ypsA |
(r)-2-phenylpyrrolidine substitute imidazopyridazines: a new class of potent and selective pan-trk inhibitors |
|
112
|
327
|
5cvhA |
Crystal structure of ck2alpha |
|
78
|
273
|
5csxA |
Crystal structure of b-raf in complex with bi 882370 |
|
80
|
276
|
5d11A |
Kinase domain of csrc in complex with rl235 |
|
159
|
465
|
4yjnA |
Calcium-dependent protein kinase 1 from toxoplasma gondii (tgcdpk1) in complex with inhibitor uw1639 |
|
81
|
297
|
4yneA |
(r)-2-phenylpyrrolidine substitute imidazopyridazines: a new class of potent and selective pan-trk inhibitors |
|
78
|
268
|
4yhfA |
Bruton's tyrosine kinase in complex with a t-butyl cyanoacrylamide inhibitor |
|
75
|
273
|
5cswA |
B-raf in complex with dabrafenib |
|
85
|
299
|
5cyiA |
Cdk2/cyclin a covalent complex with 6-(cyclohexylmethoxy)-n-(4-(vinylsulfonyl)phenyl)-9h-purin-2-amine (nu6300) |
|
94
|
316
|
5cnoA |
Crystal structure of the egfr kinase domain mutant v924r |
|
113
|
328
|
5cx9A |
Crystal structure of ck2alpha with (methyl 4-((3-(3-chloro-4-(phenyl)benzylamino)propyl)amino)-4-oxobutanoate bound |
|
105
|
350
|
4ynoA |
Crystal structure of mapk13 at inactive form |
|
111
|
324
|
5ctpA |
Crystal structure of ck2alpha with n-(3-(3-chloro-4-(phenyl)benzylamino)propyl)acetamide bound |
|
78
|
277
|
5ci7A |
Structure of ulk1 bound to a selective inhibitor |
|
82
|
317
|
4y83A |
Crystal structure of cot kinase domain in complex with 5-(2-amino-5-(quinolin-3-yl)pyridin-3-yl)-1,3,4-oxadiazole-2(3h)-thione |
|
105
|
402
|
4yzcA |
Crystal structure of pire1alpha in complex with staurosporine |
|
81
|
289
|
4yc6A |
Cdk1/cks1 |
|
81
|
278
|
4ybkA |
C-helix-out dasatinib analog crystallized with c-src kinase |
|
76
|
307
|
4y8dA |
Crystal structure of cyclin-g associated kinase (gak) complexed with selective 12i inhibitor |
|
87
|
270
|
4yjtA |
The kinase domain of human spleen tyrosine (syk) in complex with gtc000233 |
|
91
|
267
|
4yjuA |
The kinase domain of human spleen tyrosine (syk) in complex with gtc000249 |
|
111
|
327
|
5clpA |
Crystal structure of ck2alpha with 3,4-dichlorophenethylamine bound |
|
91
|
269
|
4yjpA |
The kinase domain of human spleen tyrosine (syk) in complex with gtc000223 |
|
102
|
403
|
4yz9A |
Crystal structure of human phosphorylated ire1alpha in complex with a type iii kinase inhibitor (gsk2850163a) |
|
127
|
378
|
5afvA |
Pharmacophore-based virtual screening to discover new active compounds for human choline kinase alpha1. |
|
86
|
269
|
4yjsA |
The kinase domain of human spleen tyrosine (syk) in complex with gtc000226 |
|
82
|
269
|
4yc8A |
C-helix-out binding of dasatinib analog to c-abl kinase |
|
85
|
270
|
4yjqA |
Syk kinase domain in complex with inhibitor gtc000224 |
